Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Aura Biosciences Inc ( (AURA) ) has shared an update.
On May 11, 2026, Aura Biosciences reported first-quarter 2026 results and business developments, highlighting continued progress of its global Phase 3 CoMpass trial of bel-sar in early choroidal melanoma, which is expected to complete enrollment by mid-2026 with topline data projected in the second half of 2027. The company also advanced trials of bel-sar in choroidal metastases, ocular surface cancers and non-muscle invasive bladder cancer, while updating its corporate presentation for investors.
Aura strengthened its leadership and balance sheet in the quarter, appointing Natalie Holles as chief executive and president effective April 30, 2026, and raising approximately $280.8 million in net proceeds from an oversubscribed equity offering, part of which funded a stock repurchase. As of March 31, 2026, Aura held $114.7 million in cash, cash equivalents and marketable securities, reported a wider quarterly net loss of $33.7 million on higher R&D and G&A expenses, and indicated its capital position should support operations into the second half of 2028, underpinning its late-stage development plans for bel-sar.
The most recent analyst rating on (AURA) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Aura Biosciences Inc stock, see the AURA Stock Forecast page.
Spark’s Take on AURA Stock
According to Spark, TipRanks’ AI Analyst, AURA is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, widening losses, and rising cash burn). Offsetting factors include constructive technical momentum (price above key moving averages, positive MACD) and positive funding-related corporate events that extend runway, while valuation remains difficult to support due to negative earnings and no dividend.
To see Spark’s full report on AURA stock, click here.
More about Aura Biosciences Inc
Aura Biosciences, Inc. is a Boston-based clinical-stage biotechnology company developing precision therapies for solid tumors that aim to preserve organ function. Its lead candidate, bel-sar (AU-011), is in late-stage development for early choroidal melanoma and in early-stage trials for other ocular oncology indications and non-muscle invasive bladder cancer, targeting high unmet needs in organ-preserving oncology.
Average Trading Volume: 425,563
Technical Sentiment Signal: Buy
Current Market Cap: $539.3M
For an in-depth examination of AURA stock, go to TipRanks’ Overview page.